secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001232524-23-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q2 revenue $957M (+3% YoY); GAAP EPS $1.52 beats; raises FY guidance
--------------------------------------------------------------------------------

- Q2 total revenue $957M (+3% YoY); GAAP net income $104.4M ($1.52 diluted EPS) vs $34.7M ($0.55) prior year.
- Xywav sales $326.6M (+39% YoY); Epidiolex $202.2M (+15%); Rylaze $101.7M (+39%).
- Raises FY2023 guidance: revenue $3.725-$3.875B; non-GAAP adjusted EPS raised to $18.15-$19.00 from $16.90-$17.85.
- Repurchased $100M in shares under $1.5B program; $336M remaining as of June 30, 2023.
- Combined oxybate revenue (incl. AG royalties) $491.8M (-2% YoY); Xyrem down 41% to $159.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/0001232524-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/jazz-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001232524-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer